Research Summary

My clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer.

My basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.

Research Funding

  • July 1, 2017 - May 31, 2022 - Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA220131
  • May 12, 2014 - February 28, 2019 - Translating HP 13C MRI as a Novel Paradigm for Assessing Drug Target Inhibition, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA183071
  • September 19, 2011 - July 31, 2016 - The role of HDAC2 in hormone therapy resistance, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA152989
  • May 18, 2007 - July 31, 2012 - The Role of Selective HDAC Enzymes in Drug Sensitivity, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA122657

Education

Kantonsschule Sargans, Switzerland, Baccalaureate, 1983, Sciences, Liberal Arts
University of Bern Switzerland, Doctorate, 1990, Medicine
University of Bern Switzerland, MD Thesis, 1992, Medicine

Honors & Awards

  • 1998
    John Mendelsohn House staff Teaching Award
  • 1999
    AACR-AFLAC Young Investigators Scholar Award 1999
  • 2000, 2001
    Byrne Fund Award
  • 2003-2005
    Don Shula Career Development Award, 2003-2005
  • 2007-2008
    Greatest Number of Investigator-Initiated Trials Written & Implemented, H. Lee Moffitt Cancer Center & Research Institute
  • 2008
    Research Highlights, Department of Defense, Congressionally Directed Medical Research Programs

Selected Publications

  1. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.  View on PubMed
  2. Bao R, Surriga O, Olson DJ, Allred JB, Strand CA, Zha Y, Carll T, Labadie BW, Bastos BR, Butler M, Hogg D, Musi E, Ambrosini G, Munster P, Schwartz GK, Luke JJ Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.  View on PubMed
  3. Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, de Souza JA, Vokes EE A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.  View on PubMed
  4. Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, Wang T, Belanger B, Zhang B, Moore Y, Thiagalingam A, Anders C Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.  View on PubMed
  5. De Souza A, Tavora FA, Mahalingam D, Munster PN, Safran HP, El-Deiry WS, Carneiro BA Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.  View on PubMed
  6. Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, Grilley-Olson J, Rook AH, Hollebecque A, Wong RKS, Welsh JW, Wu Y, Morehouse C, Hamid O, Walcott F, Cooper ZA, Kumar R, Ferté C, Hong DS Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.  View on PubMed
  7. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.  View on PubMed
  8. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.  View on PubMed
  9. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.  View on PubMed
  10. Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D'Andrea AD, Konstantinopoulos PA Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.  View on PubMed
  11. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.  View on PubMed
  12. Garrett SB, Matthews TM, Abramson CM, Koenig CJ, Hlubocky FJ, Daugherty CK, Munster PN, Dohan D Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials.  View on PubMed
  13. Guglin M, Tamura R, Krischer J, Munster PN Reply: Strategies to Prevent Cardiotoxicity.  View on PubMed
  14. Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).  View on PubMed
  15. Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.  View on PubMed
  16. Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B Maintenance lenalidomide in primary CNS lymphoma.  View on PubMed
  17. Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.  View on PubMed
  18. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.  View on PubMed
  19. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.  View on PubMed
  20. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.  View on PubMed

Go to UCSF Profiles, powered by CTSI